Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Procept Biorobotics Corp (NQ: PRCT )

64.31 +2.57 (+4.16%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,143,092
Open 62.95
Bid (Size) 60.50 (2)
Ask (Size) 67.34 (1)
Prev. Close 61.74
Today's Range 60.67 - 64.89
52wk Range 24.83 - 64.89
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Intuitive Surgical Builds On Its Robotic Surgery Prowess. But Challengers Are Coming.
As new robotic surgery systems loom, Intuitive Surgical investors await a "game-changer." 
Via Investor's Business Daily
PRCT Stock Earnings: PROCEPT BioRobotics Beats EPS, Beats Revenue for Q1 2024
PRCT stock results show that PROCEPT BioRobotics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
+55.19%
+55.19%
1 Month
+38.12%
+38.12%
3 Month
+35.68%
+35.68%
6 Month
+97.21%
+97.21%
1 Year
+120.84%
+120.84%

More News

Read More
PROCEPT BioRobotics Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
From PROCEPT BioRobotics
Via GlobeNewswire
Late Breaking Abstract Presented at the Japanese Urological Association Annual Meeting on Aquablation Therapy Outcomes for Men in Japan with Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics: Q4 Earnings Insights
Via Benzinga
Earnings Scheduled For February 27, 2024
Via Benzinga
PROCEPT BioRobotics's Earnings: A Preview
Via Benzinga
PROCEPT BioRobotics Announces 12 Scientific Research Presentations on Aquablation Therapy for the Treatment of Benign Prostatic Hyperplasia at the 2024 AUA Annual Meeting
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics Corp. Announces Investor Event at 2024 AUA Annual Meeting in San Antonio, Texas
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics to Report First Quarter 2024 Financial Results on May 1, 2024 and Attend the 2024 Bank of America Healthcare Conference on May 15, 2024
From PROCEPT BioRobotics
Via GlobeNewswire
Demystifying PROCEPT BioRobotics: Insights From 4 Analyst Reviews
Via Benzinga
Truist Securities Maintains Buy Rating for PROCEPT BioRobotics: Here's What You Need To Know
Via Benzinga
PROCEPT BioRobotics Reports Fourth Quarter and Full Year 2023 Results
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics to Present at the 44th Annual TD Cowen Health Care Conference in Boston
From PROCEPT BioRobotics
Via GlobeNewswire
Procept BioRobotics Shares Are Higher Today, CEO Touts 'Strong Surgeon Interest'
Via Benzinga
PROCEPT BioRobotics® Announces Preliminary Fourth Quarter Revenue of $43.3 million to $43.6 million
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics Stock Scores Rising Relative Strength
Via Investor's Business Daily
PROCEPT BioRobotics to Present at the 35ᵗʰ Annual Piper Sandler Healthcare Conference in New York City
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics® Reports Third Quarter 2023 Financial Results and Increases 2023 Revenue Guidance
From PROCEPT BioRobotics
Via GlobeNewswire
The 7 Best Tech Stocks To Buy Now: October 2023
Via InvestorPlace
PROCEPT BioRobotics to Report Third Quarter 2023 Financial Results on November 1, 2023
From PROCEPT BioRobotics
Via GlobeNewswire
The National Institute for Health and Care Excellence Endorses Aquablation® Therapy with "Standard Arrangements" Recommendation
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics Announces New Corporate Headquarters in San Jose
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics® Receives U.S. FDA Investigational Device Exemption to Investigate Aquablation® Therapy for Prostate Cancer
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics® Announces First Commercial Aquablation Therapy Procedures in Japan
From PROCEPT BioRobotics
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.